Therapeutic approaches using ex vivo immunological modification of malignant cells have not yet been widely investigated in hematological malignancies, mostly due to the lack of an efficient vector. We have recently shown that primary cultured leukemic cells can be efficiently transduced ex vivo using retargeted adenoviral vectors. 1 Thus, leukemic cells could be collected at diagnosis of the disease, transduced ex vivo with appropriate genes, irradiated, and reinfused in the patient in order to induce an antileukemic immune response. This whole cell vaccine approach in acute leukemia has many advantages: leukemic cells are easy to collect, culture and freeze; in addition, most patients with acute leukemia achieve complete remission after conventional chemotherapy with a state of minimal residual disease (MRD) that could be eradicated by the immune response induced by a gene therapy protocol. The example of graft-versus-leukemia effect observed in allogeneic bone marrow transplantation indeed suggests that an efficient immune response can cure acute leukemia. However, the gene or combination of genes able to induce an efficient autologous antileukemic immunity is still not well defined. Several groups have reported the induction of an efficient and long-lasting immunity in murine leukemic models using against subsequent challenge with leukemic cells and had a therapeutic effect for a pre-established leukemia disease. We also found minimal residual leukemic disease by RT-PCR for 6 to 12 months in 0 to 25% of animals injected with transduced leukemic cells and surviving the challenge without evidence of disease, except in the control empty plasmid group where very few mice survived the challenge but all of those were positive by RT-PCR. These findings suggest that leukemic cell vaccination by gene transfer can induce a tumor dormancy phenomenon compatible with long-term survival. Gene Therapy (2000) 7, 1312-1316.
gene transfer of CD80 and CD86 costimulatory molecules, GM-CSF, IL2, IL12 cytokines and CD154. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, few studies have investigated the combined effects of these candidate genes. Nakazaki et al 13 and Stripecke et al 15 described a synergistic effect induced by gene transfer of both GM-CSF and CD80 cDNA, and Dilloo et al 3 reported the enhancement of antileukemic effect of CD154 by co-expression of IL2. It can also be hypothesized that GM-CSF enhances the effect of CD154 by inducing the expression of CD40 on antigen-presenting cells (APC), and that CD80 and CD154 could synergize by a positive feed back loop. All those previous gene transfer experiments in murine acute leukemia reported improvement of survival and apparent complete remission of the disease, as assessed by normality of peripheral blood cell count and bone marrow smears in vaccinated animals. However, evaluation of the minimal residual disease in long living animals after gene transfer has been made in only one study.
14 In human leukemia, many studies have suggested that minimal residual leukemic disease can be found by PCR in patients in hematological complete remission several months and sometimes several years after completion of chemotherapy. 16, 17 Factors regulating this possible leukemic dormancy remain largely unknown, but it can be hypothesized that at least in some cases, an immune response controls the residual leukemic cell population
We previously developed a syngeneic BCR/ABL leukemic model (DA1-3b cells in C3H mouse) where injec-tions of small cell numbers led to an aggressive acute leukemia.
18 DA1 IL3-dependent murine myeloid progenitor cell line was electroporated with a PCDNA3 expression vector carrying a p210 BCR-ABL cDNA, and transduced cells were selected by culture in IL-3 free medium, resulting in IL3-independent BCR/ABL expressing cells named DA1-3b. Injection of DA1-3b cells in 10-week-old C3H mice led to rapid death of all animals at cell doses equal to or higher than 10 4 , with low variability. DA1-3b leukemic cells were electroporated with a PCDNA3-Zeo expression vector (Invitrogen, Carlsbad, CA, USA) carrying CD154 (provided by Immunex, Seattle, WA, USA), GM-CSF, or CD80 cDNA (both provided by Kris Thielemans, VUB, Brussels, Belgium), and GM-CSF-IRES-CD80, CD154-IRES-CD80, CD154-IRES-GM-CSF construct allowing coexpression of both genes. After gene transfer, cells were selected by zeomycin and the resulting selected bulks were analyzed for transgene expression. First, we investigated the effect on tumorigenicity of DA1-3b cells modified by gene transfer ( Figure 1 ). We observed that DA1-3b cells transduced with CD154 showed significantly reduced tumorigenicity (P Ͻ 0.001, log-rank test). By contrast, GM-CSF and CD80 transduced cells demonstrated only a minor inhibitory effect on tumorigenicity. All combinations with CD154 transduced cells were less effective than CD154 alone. We then investigated the vaccine effect of transduced cells by three successive subcutaneous injections of irradiated cells delivered every 5 days followed 1 week later by intraperitoneous injection of wild-type DA1-3b cells (Figure 2 ). Complete protection against injection of 10 4 wild-type cells was observed in the GM-CSF-IRES-CD80 and CD154 (P = 0.003, logrank test) vaccinated mice, whereas partial protection was observed in the GM-CSF (P = 0.03, log-rank test) and CD80 group (P = 0.043, log-rank test). Challenge with 10 5 DA1-3b cells showed partial protection in the GM-CSF-IRES-CD80 group and challenge with 10 6 cells only showed minor vaccine effects. Few mice vaccinated with DA1-3b cells transfected with the PCDNA3-Zeo control empty plasmid survived, suggesting that the plasmid itself is able to induce a minor antileukemic immunity. Finally, we investigated the potential therapeutic effect of gene transfer by first injecting 10 4 wild-type DA1-3b cells followed by eight subsequent subcutaneous injections of irradiated transduced cells delivered twice a week (Figure 3) . Twenty-seven, 20, and 10% of mice survived in the GM-CSF-IRES-CD80 (P = 0.02, log-rank test), CD80 and CD154 groups, respectively.
We analyzed the minimal residual disease by RT-PCR BCR/ABL in some surviving mice (Table 1) . We detected BCR/ABL transcripts in the spleen of mice 175 days after injection of wild-type DA1-3b cells in tumorigenicity, vaccine and therapeutic experiments. Six surviving mice from the vaccine experiments were analyzed at day 340 and two mice from the control group vaccinated with PCDNA3-Zeo-transduced cells and one mice from the GM-CSF vaccine group were positive by BCR/ABL RT-PCR in the spleen. When all results of RT-PCR were summarized, we observed between 0 and 25% of surviving mice positive for BCR/ABL in the CD80, CD154, GM-CSF, GM-CSF-IRES-CD80, CD154-IRES-CD80 and CD154-IRES-GM-CSF groups, and differences between those groups were not statistically significant. However, differences between those groups and the control PCDNA3-Zeo group in which all mice were positive for BCR/ABL were statistically significant (P = 0.02, Fisher's exact test).
In this report we investigated several candidate genes for gene therapy in acute leukemia. All those genes have been successfully used in other mouse leukemic models in order to induce an efficient antileukemic immunity. Most of the experiments used single gene transfer, but three reports described synergistic effects between CD154 and IL2, and GM-CSF and CD80 gene transfer, respectively. 3, 13, 15 We observed in our model that CD154 gene transfer provided the most efficient inhibition of tumorigenicity when expressed by non-irradiated cells and induced significant protection in vaccine and therapeutic experiments. It has been previously shown that CD154 molecules activate APC, inducing expression of CD80 and CD86 molecules and production of IL12. GM-CSF enhances the expression of CD40, which is the CD154 receptor. However, we did not observe in our leukemic model a synergistic effect of co-expression of CD154 and CD80 or GM-CSF but rather a reduced performance compared with CD154. These results might suggest that molecules involved in the CD154/CD40 pathway need a tight regulation rather than the unbalanced expression induced by gene transfer. However, results obtained by co-expression of GM-CSF and CD80 were superior to those obtained with these genes expressed alone, confirming the results obtained by Stripecke et al 15 and Nakazaki et al. 13, 15 Despite this synergistic effect of combined expression of GM-CSF and CD80, survival in therapeutic experiments was only slightly improved compared with the CD154 group. This suggests that the wide range of stimulation of the immune system induced by CD154 could summarize the effect of several molecules involved in more downstream steps of the immune response.
One of the main characteristics of a gene therapy protocol in acute leukemia would be the possibility of targeting MRD after intensive chemotherapy. Several groups have reported that detection of MRD is a prognostic factor of adverse outcome in human acute leukemia. 16, 17, 19 However, when highly sensitive techniques were used to detect MRD, a variable fraction of patients in prolonged remission remained positive, suggesting a tumor dormancy phenomenon. Moreover, it has also been reported that relapse rates of leukemic patients with detection of MRD у10 −2 were three times higher than those in patients with MRD below 10 −4 . Long-term control of the residual disease has also been reported in murine lymphoma where anti-idiotypic immunity controlled the growth of lymphoma cells located in the spleen. 20 In our experiments we used a highly sensitive technique to analyze MRD, and most MRD-positive mice were detected after the second-step PCR. The only difference seen was between the group of mice injected with cells transduced with genes of potential interest and control mice injected with cells transfected with the control CD154  13  0  2  GMCSF-IRES-CD80  12  0  3  CD154-IRES-GMCSF  13  0  2  CD154-IRES-CD80  8  0  2 Control group indicates mice which had never received DA1-3b cells. Total RNA was extracted from the removed spleen of mice. RT-PCR for BCR/ABL was performed as previously described, using two-step PCR with nested primers and K562 and DA1-3b as positive control cell lines. 19 In our hands, the sensitivity of this PCR technique is 10 −4 cells after one round and at least 10 −6 after two rounds. Precautions were taken to minimize contamination problems, as previously published. plasmid, where all mice were positive for MRD. Although the number of mice analyzed was small, these findings suggest that genes and combinations of genes used in our experiments not only improved survival but also the control of MRD. Cellular vaccines apparently cleared the MRD independently of which gene had been used in vaccine formulation. These findings suggest that immune responses against active disease or MRD are distinct events. MRD is probably composed of non-cycling cells, expressing fewer or other tumor antigens than cycling cells. Thus, the efficacy of immunization against leukemic disease induced by gene transfer experiments must be evaluated both for results of survival and MRD analysis. Positive BCR/ABL mice in long-term remission probGene Therapy ably carried a low tumor mass, probably a few thousand cells. Survival results obtained by gene transfer were substantially better when leukemia was induced by injection of only 10 4 leukemic cells. Thus, the antileukemic immunity induced with CD154 or combined GM-CSF and CD80 gene transfer does not seem to be able to eradicate large numbers of leukemic cells in our model. In a clinical setting, the total number of leukemic cells after the first course of intensive chemotherapy remains high, but decreases after completion of consolidation chemotherapy. A clinical protocol of gene transfer vaccine in acute leukemia would probably be more effective after consolidation treatment using several courses of chemotherapy leading to a sustained complete remission with lower possible MRD and re-injections of ex vivo transduced cells.
